By Leila Martyn, Founder of MyOva

Nobody warned you.

That's the thing most women say, eventually. Looking back, they can trace the beginning — the sleep that stopped working, the anxiety that appeared from nowhere, the periods that suddenly became unpredictable after decades of regularity, the brain that felt like it was operating through fog. But they didn't have a name for it. They didn't know it could start in their early forties. They didn't know it could last a decade.

They went to their GP and were told their bloods were normal. Or were offered antidepressants. Or were told "it's probably your age."

Perimenopause is one of the most significant physiological transitions a woman moves through in her lifetime. It affects every system in the body — not just the reproductive system. It reshapes metabolism, brain chemistry, cardiovascular function, bone density, mood, sleep architecture, and stress resilience. And yet the majority of women enter it completely unprepared, and the majority of healthcare encounters fail to explain what is actually happening.

This guide is the thing most women wish they'd had earlier.

It covers what perimenopause actually is, what drives every symptom, how to tell the difference between perimenopause and other conditions, what the long-term health picture looks like, and what an evidence-based approach to navigating it looks like in practice. No fluff. No "embrace the change" platitudes. Just clear, clinically grounded information that treats you as the intelligent adult you are.

Perimenopause is the hormonal transition period leading up to menopause — defined clinically as the point at which a woman has not had a period for 12 consecutive months [1]. Everything before that 12-month mark, from the first signs of hormonal change, is perimenopause.

In the UK, the average age for menopause is 51 [1]. Early perimenopause typically begins around age 47, with late perimenopause averaging around 49 [2]. But these are averages — and the range is wide. Some women begin experiencing perimenopausal symptoms in their late thirties. Some don't notice significant changes until their late forties. There is no single timeline.

What defines perimenopause is not a specific age. It is a specific hormonal pattern: the beginning of ovarian decline, characterised by increasingly irregular ovulation, rising FSH (follicle-stimulating hormone), and the erratic fluctuation — not the steady decline — of oestrogen [3].

This distinction matters enormously. Perimenopause is not simply "low oestrogen." In early perimenopause especially, oestrogen can spike higher than it did during the reproductive years before dropping. It's the unpredictability and eventual loss of rhythm that drives symptoms — not a linear decline from high to low [3].

Perimenopause is generally understood to last between four and ten years [4]. The experience of it varies significantly between women — some have relatively few symptoms, while others experience a degree of disruption that meaningfully affects their work, relationships, cognitive function, and quality of life.

You are not imagining it. And you were not supposed to just get on with it.

Understanding where you are in the transition helps enormously with both diagnosis and expectations.

Early perimenopause is characterised by changes in menstrual cycle pattern — cycles becoming slightly shorter, longer, heavier, lighter, or more irregular — while periods are still occurring with some regularity. FSH begins to rise as the brain attempts to stimulate increasingly unresponsive ovaries. Oestrogen may spike unpredictably. Progesterone production, which depends on ovulation occurring, begins to decline as ovulatory cycles become less consistent [3].

The symptom experience in early perimenopause is often dominated by psychological symptoms — anxiety, mood changes, brain fog, sleep disruption — rather than the hot flushes most women associate with menopause. This is one of the main reasons perimenopause is missed or misdiagnosed: the psychological symptoms arrive first, without the classic vasomotor symptoms that prompt recognition.

Late perimenopause is characterised by increasingly infrequent periods — typically 60 days or longer between cycles — more pronounced vasomotor symptoms as oestrogen levels fall more consistently, and accelerating bone loss [5]. FSH levels are significantly elevated. Hot flushes and night sweats are more likely to be prominent in this stage.

Both stages require understanding. Both stages are manageable. Neither stage requires simply enduring symptoms without investigation or support.

This is the section that changes how women understand their experience. Because once the mechanism is clear, the symptoms stop feeling random.

Oestrogen is not a single hormone. It is a class of hormones — predominantly oestradiol during the reproductive years — that regulates far more than the reproductive system. Oestrogen influences [6]:

• Brain function — serotonin synthesis and receptor sensitivity, dopamine signalling, synaptic plasticity, and cerebral blood flow
• Thermoregulation — the hypothalamic thermostat that controls body temperature
• Bone metabolism — inhibiting bone resorption and protecting bone density
• Cardiovascular function — arterial compliance, lipid metabolism, and vascular inflammation
• Metabolic regulation — insulin sensitivity, fat distribution, and glucose metabolism
• Vaginal and urogenital tissue — mucosal integrity, pH, and pelvic floor support

When oestrogen fluctuates erratically — spiking and plunging unpredictably rather than following the reliable rhythm of the reproductive years — every one of these systems is affected [6]. This is why perimenopause is not a reproductive condition. It is a whole-body transition.

Progesterone often receives less attention than oestrogen in perimenopause discussions — but its decline is frequently the first hormonal shift and often the driver of the earliest symptoms.

Progesterone is produced by the corpus luteum after ovulation. As perimenopause approaches and ovulation becomes less frequent or less complete, progesterone output falls — often significantly — while oestrogen may still be fluctuating at relatively high levels [3].

Low progesterone has specific neurological effects: progesterone metabolises to allopregnanolone, a neurosteroid that enhances GABA receptor activity and produces calming, sleep-supportive effects on the brain [7]. When progesterone declines, the brain loses this natural calming buffer. The result is often anxiety, sleep fragmentation, night-time wakefulness, and emotional lability — appearing before hot flushes, often before cycle changes are dramatic, and almost invariably before a GP considers perimenopause as a diagnosis [7].

As ovarian responsiveness declines, the pituitary gland works harder — producing increasing amounts of FSH to try to stimulate follicle development. Rising FSH is a clinical marker of perimenopause, though it is not a reliable single-test diagnostic because levels fluctuate dramatically day to day in early perimenopause [3].

This is one of the most important things to understand about hormone testing in perimenopause: a single blood test showing "normal" FSH does not exclude perimenopause. A longitudinal picture — tracking symptoms alongside hormonal markers over time — is far more diagnostically informative than any single reading [3].

The British Menopause Society identifies over 34 potential symptoms of perimenopause [8]. Most women experience a subset — but that subset is often more extensive, and more disruptive, than they were prepared for.

Hot flushes and night sweats are the most recognised perimenopause symptoms — and they affect approximately 75–80% of women during the menopausal transition [9]. They are driven by destabilisation of hypothalamic thermoregulation as oestrogen fluctuates. The thermostat's tolerance zone narrows, and what would previously have been an unremarkable change in core body temperature now triggers an emergency cooling response: rapid vasodilation, increased skin blood flow, and sweating.

Hot flushes are not cosmetic inconveniences. Severe hot flushes disrupt sleep, affect concentration, impair work performance, and for many women represent one of the most functionally significant aspects of perimenopause.

→ Read: Does Sage Actually Help With Hot Flushes? Here's What the Research Says

→ Read: Red Clover for Menopause: Plant Oestrogen or Overhyped Herb?

Around 40% of perimenopausal women experience significant sleep problems [10]. The mechanisms are multiple and interrelated:

• Night sweats interrupt sleep continuity directly
• Declining progesterone reduces GABA-mediated sleep onset and depth [7]
• Rising cortisol disrupts circadian rhythm and early morning waking
• Anxiety — itself hormonally driven — prevents sleep onset

Sleep disruption in perimenopause is not simply a matter of managing hot flushes. It is a neurological and hormonal phenomenon requiring a multifaceted approach. And disrupted sleep compounds virtually every other perimenopausal symptom — worsening brain fog, amplifying mood instability, accelerating metabolic changes, and reducing stress resilience.

Up to 40% of perimenopausal women experience clinically significant anxiety or depression [11]. This is not a coincidence, and it is not a psychological response to "getting older."

Oestrogen directly influences serotonin synthesis and receptor sensitivity. As oestrogen fluctuates, so does the stability of the serotonergic system [6]. Progesterone decline removes the GABA-calming buffer. The HPA axis — the stress response system — becomes more reactive as oestrogen declines, amplifying cortisol responses to ordinary life stressors [12].

The result is anxiety that feels disproportionate, low mood that doesn't track with life circumstances, emotional volatility, and sometimes depression — in women who have never previously experienced mental health difficulties.

The most important clinical distinction here: mood symptoms in perimenopause have a hormonal driver. Treating them with antidepressants alone, without addressing the underlying endocrine shift, often produces limited improvement — because the root cause remains unaddressed.

→ Read: Why Your Hormones Feel Off — And What to Do About It

Brain fog — the experience of reduced mental sharpness, memory lapses, difficulty concentrating, reduced verbal fluency — is one of the most distressing and least discussed symptoms of perimenopause.

It is rooted in the same hormonal mechanism as mood changes: oestrogen's influence on dopamine signalling, synaptic plasticity, and cerebral blood flow [6, 7]. When oestrogen fluctuates, cognitive performance fluctuates with it. Women frequently report feeling cognitively unreliable — unable to trust their memory or concentration in the way they always had.

The research is reassuring on one critical point: the cognitive changes of perimenopause are not permanent neurodegeneration. For most women, as oestrogen stabilises post-menopause, the acute brain fog improves [6]. This is not Alzheimer's beginning. This is a transitional neurological adjustment — significant and disruptive, but not irreversible.

Cycle changes are among the first signs of early perimenopause — and they are highly variable. Cycles may become shorter, then longer. Periods may become heavier before eventually lightening. Spotting between periods may appear. Cycles may be skipped entirely [10].

The mechanism is straightforward: as ovulation becomes less reliable, the progesterone signal that triggers menstruation becomes inconsistent. Without adequate progesterone, the endometrium may build up for longer before shedding — resulting in heavier, more prolonged periods. Anovulatory cycles — cycles in which no egg is released — produce oestrogen without the progesterone counterbalance, compounding this effect.

Heavy perimenopausal periods are common and deserve investigation — both to confirm the hormonal aetiology and to rule out other causes including fibroids, endometriosis, and in rare cases, endometrial pathology.

Many women notice weight redistribution during perimenopause — specifically, fat accumulation around the abdomen — even without significant changes to diet or exercise. This is not a failure of discipline. It is a metabolic recalibration driven by hormonal change [6].

Oestrogen plays a protective role in insulin sensitivity and metabolic function. As it declines, insulin resistance tends to increase. Cortisol rises — driven by HPA axis dysregulation — further raising blood glucose and driving abdominal fat deposition. The liver's handling of lipids changes, with total cholesterol and LDL typically rising as oestrogen declines [13].

Muscle mass preservation becomes critically important during this period. Lean muscle is a primary driver of insulin sensitivity and metabolic rate. Prioritising resistance training, adequate protein intake, and sleep quality are among the most evidence-backed strategies for managing perimenopausal metabolic shifts.

Joint aches, stiffness, and musculoskeletal discomfort are frequently reported in perimenopause — and are often attributed to ageing rather than hormones. Oestrogen has anti-inflammatory properties and plays a role in joint lubrication and cartilage health. As levels fluctuate, inflammatory sensitivity increases and connective tissue becomes less well-supported [8].

Declining oestrogen affects the vaginal and urogenital tissues — thinning the vaginal mucosa, reducing natural lubrication, altering pH, and reducing the resilience of pelvic floor structures. Symptoms include vaginal dryness, discomfort during sex, urinary urgency, and increased susceptibility to urinary tract infections [8].

These symptoms — collectively termed the Genitourinary Syndrome of Menopause (GSM) — are extremely common and extremely underreported due to the embarrassment many women feel about them. They are treatable, and they deserve a direct conversation with a healthcare provider.

This is one of the most frustrating aspects of perimenopause for women seeking diagnosis and validation.

Because perimenopause in its early stages is characterised by fluctuating rather than consistently low hormones, a single blood test — taken on any given day — may show oestrogen levels that appear within the normal reproductive range, FSH levels that don't yet indicate ovarian decline, and progesterone that looks adequate [3].

The result: a woman experiencing debilitating symptoms is told her bloods are normal. She is offered antidepressants. She leaves without a diagnosis.

The clinical picture is confirmed not by a single blood test but by the pattern of symptoms in context of age and cycle changes. NICE guidelines state that perimenopause should be diagnosed clinically — based on symptom history — in women aged 45 and over, without the need for confirmatory hormone testing [1].

If you are between 45 and 55 and experiencing symptoms consistent with perimenopause, you do not need a blood test to confirm the diagnosis. You need a clinician who understands how to take a proper symptom history and is willing to discuss your options.

If your GP dismisses your symptoms without this conversation, you are entitled to ask for a referral — to a gynaecologist with a specialist interest in menopause, a British Menopause Society-accredited specialist, or a menopause clinic.

Oestrogen does not only regulate reproduction. Its decline creates specific long-term health risks that most women are never told about — and the perimenopausal window is the optimal time to address them.

Oestrogen is a primary regulator of bone metabolism — inhibiting osteoclasts (bone-resorbing cells) and supporting bone formation. As it declines, bone resorption accelerates.

The SWAN bone study — a large multi-ethnic cohort of over 2,000 women — found that lumbar spine bone loss becomes measurable approximately two years before the final menstrual period, with annualised loss rates rising from 1.7% in perimenopause to 3.3% in the two years immediately post-menopause [14]. In a two-year prospective study, approximately 24% of perimenopausal women were classified as "fast bone losers" — losing more than 7% of bone mineral density in 24 months [15].

Bone loss is clinically silent. It goes unaddressed unless actively managed. Bone-protective strategies — resistance training, adequate calcium and Vitamin D, and HRT consideration where appropriate — are most effective when begun during perimenopause, before significant structural compromise has occurred.

As oestrogen declines, total cholesterol rises, LDL increases, and HDL typically falls [13]. Arterial stiffness increases. The cardiovascular protective effect of oestrogen — which has maintained a more favourable risk profile than age-matched men throughout the reproductive years — is progressively removed.

The perimenopausal decade is a critical window for cardiovascular optimisation. The foundations built now significantly affect long-term outcomes.

Insulin resistance increases as oestrogen declines — driving not just weight redistribution but broader deterioration in metabolic markers including fasting glucose, blood pressure, lipid profiles, and inflammatory markers [6]. For women who already have PCOS-related insulin resistance, perimenopause can compound an existing vulnerability significantly — making metabolic strategy during this transition particularly important.

Hormone replacement therapy remains the most clinically effective intervention for perimenopausal and menopausal symptoms. The evidence for its effectiveness on vasomotor symptoms, sleep, mood, cognitive function, bone protection, and cardiovascular risk management (when initiated in the perimenopausal window) is substantial [1].

The fear surrounding HRT — largely stemming from the 2002 Women's Health Initiative study, which was misinterpreted and misreported — has been substantially revised by subsequent research. Current clinical consensus, as reflected in updated NICE guidance and British Menopause Society guidelines, supports HRT as a safe and effective option for most healthy women under 60 and within 10 years of menopause [1].

What the evidence supports:

• Body-identical (bioidentical) oestrogen delivered transdermally (patch, gel, spray) does not carry the same clotting and stroke risks associated with older oral synthetic oestrogen formulations
• Micronised progesterone (Utrogestan) is better tolerated and associated with lower cardiovascular and breast cancer risk than older synthetic progestins
• The risk-benefit profile of HRT is favourable for most women experiencing moderate to severe symptoms
• Beginning HRT during the perimenopausal window — rather than waiting until postmenopause — appears to offer greater cardiovascular and cognitive protective benefit

What the evidence doesn't support: treating HRT as suitable for every woman without individual assessment. Women with certain risk factors — personal history of oestrogen-sensitive cancers, certain clotting disorders, specific cardiovascular conditions — require individual evaluation and discussion with a specialist.

The decision about HRT is a clinical one that belongs between you and a clinician with appropriate expertise in menopause medicine. What this article can do is ensure you arrive at that conversation informed — neither frightened by outdated statistics nor uninformed about the benefits.

For women who choose not to take HRT, are waiting to discuss it, or who want to support the hormonal transition through all available evidence-based strategies — the following areas have genuine research support.

Phytoestrogens are plant compounds that interact mildly with oestrogen receptors — providing a degree of oestrogenic activity when circulating oestrogen is declining. Red Clover isoflavones have the most extensive clinical evidence base for vasomotor symptom relief — with a 2021 meta-analysis of multiple RCTs demonstrating statistically significant reductions in daily hot flush frequency, alongside mood and sleep improvements as secondary outcomes [16].

→ Read: Red Clover for Menopause: Plant Oestrogen or Overhyped Herb?

Shatavari (Asparagus racemosus) is an Ayurvedic botanical with adaptogenic and phytoestrogenic properties, traditionally used for female hormonal transitions across the lifecycle.

Sage (Salvia officinalis) has a growing clinical evidence base for hot flush relief through a neurological rather than purely oestrogenic mechanism — modulating serotonin, GABA, and adrenergic receptor activity in the hypothalamus. A 2011 multicentre trial demonstrated a 64% reduction in intensity-rated hot flushes over eight weeks [17].

→ Read: Does Sage Actually Help With Hot Flushes? Here's What the Research Says

The HPA axis becomes more reactive as oestrogen declines — meaning cortisol spikes more easily, is less efficiently cleared, and compounds both sleep disruption and mood instability. Adaptogenic botanicals that demonstrably modulate HPA axis activity are therefore directly relevant to perimenopausal symptom burden.

KSM-66® Ashwagandha has substantial clinical evidence for cortisol reduction, stress resilience, and sleep quality improvement → Read our full Ashwagandha guide.

Holy Basil (Ocimum tenuiflorum) offers complementary HPA axis modulation through CRH-R1 and 11β-HSD1 inhibition — reducing cortisol amplification in peripheral tissues and supporting blood sugar stability → Read: Holy Basil for Hormones: The Adaptogen You've Never Heard Of.

Systemic inflammation rises as oestrogen declines — oestrogen has anti-inflammatory properties, and its loss removes a degree of inflammatory regulation the body has relied on for decades. Anti-inflammatory dietary patterns directly support the hormonal transition by reducing the inflammatory load that amplifies every perimenopausal symptom.

Turmeric (curcumin) has specific evidence for anti-inflammatory and neuroprotective activity relevant to perimenopausal symptom management.

→ Read: Anti-Inflammatory Eating for Hormonal Health

The MyOva Hormone Balance Supplement addresses the specific hormonal and neurological pathways disrupted during perimenopause — each ingredient chosen for a defined mechanism rather than general wellness association:

• Red Clover (10:1 extract) — phytoestrogen support via ERβ receptor activity; vasomotor symptom relief, bone and cardiovascular support
• Sage leaf (10:1 extract, 4% rosmarinic acid) — hypothalamic thermoregulatory support through serotonin, GABA and adrenergic receptor modulation; hot flush and night sweat reduction
• Shatavari (5:1 extract) — adaptogenic and phytoestrogenic support for hormonal transition across the lifecycle
• KSM-66® Ashwagandha — cortisol modulation via HPA axis regulation; stress resilience and sleep quality support
• Holy Basil (4:1 extract) — complementary HPA axis support via CRH-R1 and 11β-HSD1 inhibition; blood sugar stability
• Chamomile (10:1 extract) — GABA-adjacent nervous system calming; sleep onset and anxiety reduction
• Turmeric (95% curcuminoids) — anti-inflammatory and neuroprotective support as oestrogen's anti-inflammatory protection declines
• Rosemary (10:1 extract) — oestrogen metabolism support; antioxidant protection
• Fennel (6:1 extract) — traditionally used for vasomotor and hormonal cycle support
• Pyridoxal-5'-Phosphate (active B6) — serotonin, GABA and dopamine synthesis; oestrogen metabolism support

It is not a replacement for HRT. It is a considered, evidence-led botanical formula for women navigating perimenopause who want to support the transition through every available, evidence-backed pathway.

→ Explore the MyOva Hormone Balance Supplement

Perimenopause presents a specific and under-recognised challenge for women who already have PCOS. The insulin resistance, androgen excess, and metabolic disruption of PCOS doesn't resolve at perimenopause — it intersects with the hormonal transition in ways that can significantly amplify symptoms and long-term metabolic risk.

MyOva Menoplus was created specifically for this crossover — the first menopause supplement formulated for women with PCOS. Here's what each ingredient is doing:

• Myo-Inositol and D-Chiro Inositol — the inositol combination with the most extensive clinical evidence base for insulin sensitivity, ovarian function, and hormonal regulation in PCOS. As insulin resistance worsens during the perimenopausal transition, inositol support directly addresses the metabolic driver that underpins many PCOS symptoms
• Shatavari (5:1 extract) — adaptogenic and phytoestrogenic support for the hormonal transition, with traditional use for female reproductive health across all lifecycle stages
• Sage leaf (10:1, 4% rosmarinic acid) — the same standardised extract as in the Hormone Balance formula; thermoregulatory support for hot flushes and night sweats via neurological receptor modulation
• Red Clover (8% isoflavones) — phytoestrogen support for vasomotor symptoms, bone metabolism, and cardiovascular health as oestrogen declines
• Maca (10:1 extract) — adaptogenic root with evidence for energy, mood, and libido support in perimenopausal and postmenopausal women; addresses the fatigue and low mood that frequently accompany the transition
• Hop (4:1 extract) — Humulus lupulus contains 8-prenylnaringenin, one of the most potent phytoestrogens identified in plant sources; supports vasomotor symptom relief alongside Red Clover and Sage
• Pyridoxal-5'-Phosphate (active B6) — direct serotonin, GABA and dopamine synthesis support; oestrogen metabolism; mood and neurological stability across the cycle
• Calcium L-Methylfolate — the active, bioavailable form of folate; supports methylation, homocysteine management, and neurological function — all of which are relevant to the mood and cognitive symptoms of perimenopause
• Vitamin B12 (Methylcobalamin) — the active B12 form; supports energy metabolism, neurological function, and homocysteine regulation alongside methylfolate

For women with PCOS, the perimenopausal transition is not the same as for women without it. Insulin resistance worsens as oestrogen declines. The metabolic protective effect of oestrogen is removed while PCOS-related metabolic vulnerability remains. Menoplus addresses this dual challenge — supporting both the menopausal transition and the underlying PCOS hormonal environment simultaneously.

→ Explore the MyOva Menoplus Supplement

Resistance training. The single most important exercise intervention in perimenopause. Lean muscle mass drives insulin sensitivity, metabolic rate, bone density, and physical resilience. High-intensity training can amplify cortisol in women whose HPA axis is already reactive — resistance-based movement is better suited to this phase.

Protein prioritisation. Muscle protein synthesis requires adequate protein — especially as muscle becomes harder to build with oestrogen decline. Target 1.6–2g per kg of body weight daily in active perimenopausal women.

Blood sugar stability. Managing postprandial glucose spikes reduces insulin demand, cortisol-driven glucose fluctuation, and abdominal fat accumulation. Fibre-first eating, protein at every meal, and reducing ultra-processed food load are the most effective levers.

Sleep protection. Sleep regulates cortisol rhythm, inflammatory markers, and hormonal balance. Protecting sleep architecture through perimenopausal disruption is a clinical priority — not a lifestyle preference.

Stress management. The HPA axis is more reactive as oestrogen declines, and cortisol is cleared less efficiently. Adaptogenic botanical support, parasympathetic activation (slow breathing, yoga), and workload management all have direct physiological relevance in this context.

This section is practical and direct — because many women in perimenopause have had dismissive medical encounters, and preparation makes a meaningful difference.

Track before you go. Two to three months of daily symptom tracking — noting symptom type, severity, cycle day, sleep, and mood — gives you evidence rather than a description. Bring that data.

Use the right language. "I believe I'm in perimenopause and I'd like to discuss my options" is more specific and harder to dismiss than "I haven't been feeling well."

Know your rights. NICE guidelines state that women aged 45 and over presenting with typical perimenopause symptoms should be diagnosed clinically without requiring confirmatory hormone tests. If you are offered a blood test as a reason to delay diagnosis, cite NICE NG23.

Ask specific questions. "What are my options for managing vasomotor symptoms?" "Can we discuss HRT — both the benefits and my personal risk factors?" "Is there a menopause specialist or BMS-accredited clinic I can be referred to?"

Request a referral if needed. If your GP lacks confidence or knowledge in menopause medicine — which the evidence suggests is common, with training highly variable — you are entitled to ask for a referral to a specialist.

Most perimenopausal symptoms, while disruptive, are not medically urgent. However, the following require prompt medical attention:

• Bleeding between periods, after sex, or after a period of amenorrhoea
• Very heavy or prolonged bleeding that causes anaemia
• Mood symptoms severe enough to affect safety (seek immediate support via your GP, 111, or Samaritans on 116 123)
• Chest pain, palpitations, or symptoms of cardiovascular concern
• Any symptom that feels acutely wrong, regardless of what you've read

Perimenopause is not a malfunction. It is a transition — a significant, multi-year physiological recalibration that reshapes your endocrine system, brain chemistry, metabolic function, and long-term health landscape simultaneously.

It starts earlier than most women expect. It lasts longer. It affects more systems. And it is navigated most effectively not by waiting for it to pass, but by understanding what is driving each symptom, addressing the underlying mechanisms where possible, and making the specific lifestyle and nutritional investments that pay dividends well beyond the transition itself.

You deserve more than "it's your age."

You deserve a clear explanation, a considered set of options, and a plan you can build confidence in.

That starts with understanding what is actually happening.

How do I know if I'm in perimenopause? The most reliable indicators are: cycle changes (irregular, heavier, lighter, or skipped periods) combined with mood, sleep, or vasomotor symptoms in a woman aged 40 or over. NICE guidelines support clinical diagnosis based on symptoms in women over 45 without requiring blood tests.

Can I get pregnant during perimenopause? Yes — until menopause is confirmed (12 months without a period), pregnancy remains possible. Contraception should continue until menopause is confirmed if pregnancy is not wanted.

Does perimenopause affect women differently based on ethnicity? Yes. Research indicates that Black women tend to experience longer and more severe vasomotor symptoms. South Asian women may experience earlier onset in some populations. These differences deserve recognition in clinical assessment.

What is the difference between perimenopause and menopause? Perimenopause is the transition phase, from first hormonal changes until 12 months after the last period. Menopause is the specific point — confirmed retrospectively — at which 12 consecutive months without a period have elapsed.

Is perimenopause the same as "the change"? "The change" typically refers to the entire menopausal transition, which includes perimenopause, menopause itself, and postmenopause. Perimenopause is the longest and often most symptomatic phase of this transition.

Can perimenopause start in my thirties? Early perimenopause can begin in the late thirties for some women. Symptoms before 40 warrant investigation to rule out primary ovarian insufficiency (POI), which has different management implications and requires specialist review.

What if my GP dismisses my symptoms? Ask specifically for a referral to a menopause specialist or BMS-accredited clinic. You can also self-refer to private menopause clinics, and a growing number of NHS integrated care systems have dedicated menopause services. The Menopause Charity and Menopause Support UK both provide GP referral letter templates.

1. National Institute for Health and Care Excellence. Menopause: Diagnosis and Management. NICE Guideline NG23. Updated 2019. Available at: nice.org.uk/guidance/ng23

2. Chemist4U. Menopause Statistics 2025 — the latest facts and stats. 2026. Available at: chemist-4-u.com

3. Oova Health. Progesterone During Perimenopause: Symptoms, Testing and Treatment. 2023. Available at: oova.life

4. npj Women's Health. Perimenopause symptoms, severity, and healthcare seeking in women in the US. 2025. doi:10.1038/s44294-025-00061-3

5. Lamkin Clinic. Perimenopause: Symptoms, Testing, and Functional Medicine Treatment. 2026. Available at: lamkinclinic.com

6. Dale Pinnock. Key Hormonal Shifts: Oestrogen and Progesterone in the Menopausal Transition. 2025. Available at: dalepinnock.com

7. Cleopatra Rx. Perimenopause Brain Fog Explained: What Is Happening to Your Brain. 2025. Available at: cleopatrarx.com

8. British Menopause Society. BMS Tool for Clinicians: What is the Menopause? 2023. Available at: thebms.org.uk

9. Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44(3):497–515. doi:10.1016/j.ecl.2015.05.001

10. Harvard Health. Perimenopause: Rocky Road to Menopause. 2022. Available at: health.harvard.edu

11. MIT Health. FAQ: Understanding Perimenopause and Menopause. 2024. Available at: health.mit.edu

12. Hantsoo L, Epperson CN. Towards understanding the biology of premenstrual dysphoric disorder. Neuroscience & Biobehavioral Reviews. 2020;115:252–268. doi:10.1016/j.neubiorev.2020.02.025

13. Luo et al. Association of Changes in Relevant Indicators With Cardiovascular Disease and Osteoporosis in Perimenopausal and Postmenopausal Women. Food Science & Nutrition. 2024. doi:10.1002/fsn3.4512

14. Finkelstein JS, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women (SWAN Bone Study). J Clin Endocrinol Metab. 2008. doi:10.1210/jc.2007-1876

15. Bider-Canfield Z, et al. Perimenopausal Bone Loss Is Associated with Ovulatory Activity — Results of the PeKnO Study. Nutrients. 2022. doi:10.3390/nu14030561

16. Kanadys W, et al. Evaluation of clinical meaningfulness of red clover extract to relieve hot flushes in peri- and post-menopausal women: a systematic review and meta-analysis. Nutrients. 2021;13(4):1258. doi:10.3390/nu13041258

17. Bommer S, Klein P, Suter A. First time proof of sage's tolerability and efficacy in menopausal women with hot flushes. Adv Ther. 2011;28(6):490–500. doi:10.1007/s12325-011-0027-z

This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any new supplement or making changes to existing medical treatment. If you are experiencing mood symptoms that affect your safety, please contact your GP, call 111, or reach Samaritans on 116 123 (free, 24/7).